Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) treated successfully with tissue plasminogen activator

Archives of Dermatology

Volumn 142, Issue 11, 2006, Pages 1466-1469

  Deng, April ^a   Gocke, Christopher D ^a   Hess, John ^a   Heyman, Meyer ^a   Paltiel, Michael ^a   Gaspari, Anthony ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; DIPYRIDAMOLE; ENOXAPARIN; HEPARIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDNISONE; TISSUE PLASMINOGEN ACTIVATOR; WARFARIN;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DOSE RESPONSE; FEMALE; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; LABORATORY TEST; LIVEDO RETICULARIS; LIVEDOID VASCULOPATHY; PRIORITY JOURNAL; SKIN BIOPSY; TREATMENT RESPONSE; VASCULAR DISEASE; VASCULITIS;

ADULT; ANTICOAGULANTS; DIAGNOSIS, DIFFERENTIAL; DNA; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPARIN; HUMANS; LEG ULCER; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROMOTER REGIONS (GENETICS); SKIN DISEASES, VASCULAR; TISSUE PLASMINOGEN ACTIVATOR;

EID: 33751224754     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.142.11.1466     Document Type: Article

References (19)

1. Jorizzo JL. Livedoid vasculopathy: what is it? Arch Dermatol. 1998;134:491-493.
2. McCalmont CS, McCalmont AL, Jorizzo JL, White WL, Leshin B, Rothberger H. Livedovasculitis: vasculitis or thrombotic vasculopathy? Clin Exp Dermatol. 1992;17:4-8.
3. Biedermann T, Flaig MJ, Sander CA. Livedoid vasculopathy in a patient with factor V mutation (Leiden). J Cutan Pathol. 2000;27:410-412.
4. Boyvat A, Kundakci N, Babikir MOA, Gurgey E. Livedoid vasculopathy associated with heterozygous protein C deficiency. Br J Dermatol. 2000;143:840-842.
5. Cocuroccia B, Tonanzi T, Menaguale G, Fazio M, Girolomoni G. Livedoid vasculopathy and skin ulcers in patients with inherited thrombophilia. Eur J Dermatol. 2002;12:360-363.
6. Klein KL, Pittelkow MR. Tissue plasminogen activator for treatment of livedoid vasculitis. Mayo Clin Proc. 1992;67:923-933.
7. Papi M, Didona B, De Pita O, et al. Livedo vasculopathy vs small vessel cutaneous vasculitis: cytokine and platelet P-selectin studies. Arch Dermatol. 1998;134:447-452.
8. Hairston BR, Davis MDP, Gibson LE, Drage LA. Treatment of livedoid vasculopathy with low-molecular-weight heparin. Arch Dermatol. 2003;139:987-990.
9. Browning CE, Callen JP. Warfarin therapy for livedoid vasculopathy associated with cryofibrinogenemia and hyperhomocysteinemia. Arch Dermatol. 2006;142:75-78.
10. Francis CW. Plasminogen activator inhibitor-1 levels and polymorphisms: association with venous thromboembolism. Arch Pathol Lab Med. 2002;126:1401-1404.
11. Samad F, Uysal KT, Wiesbrock SM, Pandey M, Hotamisiligil GS, Loskutoff DJ. Tumor necrosis factor-α is a key component in the obesity-linked elevation of plasminogen activator inhibitor I. Proc Natl Acad Sci U S A. 1999;96:6902-6907.
12. Weckroth M, Vaheri A, Virolainen S, Saarialho-kere U, Jahkola T, Siren V. Epithelial tissue-type plasminogen activator expression, unlike that of urokinase, its receptor, and plasminogen activator inhibitor-1, is increased in chronic venous ulcers. Br J Dermatol. 2004;151:1189-1196.
13. Dawson S, Hamsten A, Wiman B, Henney A, Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasminogen activator inhibitor-1 activity. Arteriosclerosis Thromb. 1991;11:183-190.
14. Eriksson P, Kallin B, van't Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen activator inhibitor-1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A. 1995;92:1851-1855.
15. Burzotta F, DiCastelnuovo A, Amore A, et al. 4G/5G promoter PAI-1 gene polymorphism is associated with plasmatic PAI-1 activity in Italians: a model of gene-environment interaction. Thromb Haemost. 1998;79:354-358.
16. Burzotta F, Iacoviello L, Di Castelnuovo A, et al. 4G/5G PAI-1 promoter polymorphism and acute-phase levels of PAI-1 following coronary bypass surgery: a prospective study. J Thromb Thrombolysis. 2003;16:149-154.
17. Vergouwen MD, Frijins CJ, Roos YB, Rinkel GJ, Vermeulen M. Plasminogen activator inhibitor-1 4G allele in the 4G/5G promoter polymorphism increases the occurrence of cerebral ischemia after aneurysmal subarachnoid hemorrhage. Stroke. 2004;35:1280-1283.
18. Czekay RP, Loskutoff DJ. Unexpected role of plasminogen activator inhibitor 1 in cell adhesion and detachment. Exp Biol Med (Maywood). 2004;229:1090-1096.
19. Bajou K, Maillard C, Jost M, et al. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene. 2004;23:6986-6990.